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Abstract
The EFSA Panel on Food Additives and Flavourings (FAF) provides a scientific opinion on the safety of
the proposed amendment of the specifications for steviol glycosides (E 960) as a food additive, in
particular to expand the list of steviol glycosides to 60 steviol glycosides identified in the leaves of
Stevia Rebaudiana Bertoni. With the existing specifications, the food additive must be comprised of not
less than 95% of the 11 named steviol glycosides. The proposed change is to include all 60 steviol
glycosides in the same limit value of 95% and this would allow the presence of up to 5% of impurities.
FAF Panel considered that all steviol glycosides share the same metabolic fate, and therefore, the
safety of 60 identified steviol glycosides can be based on read-across from toxicological data previously
evaluated by EFSA and the acceptable daily intake (ADI) of 4 mg/kg body weight (bw) per day will
apply to all those steviol glycosides. However, according to the proposed change in specifications,
there remains a small but not insignificant fraction of the additive that would be undefined and
therefore cannot be evaluated by the Panel. The Panel concluded that the inclusion of the 60 steviol
glycosides in the proposed specifications for steviol glycoside (E960) would not be of safety concern.
However, the Panel cannot conclude on the safety of the proposed amendment to the specifications of
steviol glycosides (E 960) as food additive if the purity assay value of not less than 95% for the total
content of steviol glycosides is maintained.
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Summary
Following a request from the European Commission to the European Food Safety Authority (EFSA),
the Panel on Food Additives and Flavourings (FAF) was asked to provide a scientific opinion on the
safety of a proposed amendment of the specifications of the food additive steviol glycosides (E 960), in
accordance with Regulation (EC) No 1331/2008 establishing a common authorisation procedure for
food additives, food enzymes and food flavourings.
The present evaluation is based on the data on steviol glycosides in a newly submitted dossier by
the applicant and additional information submitted by the applicant during the assessment process in
response to a request by EFSA.
The safety of steviol glycosides as a food additive was evaluated by EFSA in 2010 and an
acceptable daily intake (ADI) of 4 mg/kg body weight (bw) per day, expressed as steviol equivalents.
Following a subsequent EFSA assessment in 2015 (EFSA ANS Panel, 2015a), rebaudioside D and M
were included in the specifications for steviol glycosides (E 960).
The Joint FAO/WHO Expert Committee on Food Additives (JECFA) established an ADI for steviol
glycosides of 4 mg/kg bw per day, expressed as steviol (JECFA, 2009). At the JECFA meeting in 2019,
a framework was adopted for developing specifications for steviol glycosides by four different methods
of production (JECFA, 2019). Specifications for steviol glycosides from Stevia Rebaudiana Bertoni
obtained by water extraction were prepared (JECFA, 2020).
The applicant asked to amend the existing EU specifications for steviol glycosides to allow for the
inclusion of 60 steviol glycosides identified in S. rebaudiana Bertoni leaves, including both ‘major’ and
‘minor’ steviol glycosides, that may comprise the assay value of not less than 95% total steviol
glycosides (Appendix A). With the existing specifications, the food additive must be comprised of not
less than 95% of the 11 named steviol glycosides. The proposed change is to include all 60 steviol
glycosides in the same limit value of 95% and this would allow the presence of up to 5% of impurities.
Panel noted that this proposal would allow to have commercial products of lower purity than is
currently the case.
Data on ADME of some of steviol glycosides currently listed in the EU specifications have been
considered and summarised in previous EFSA opinions (EFSA ANS Panel, 2010, 2015a). Based on the
available data set, stevioside and Rebaudioside A are not hydrolysed by digestive enzymes of the
upper gastrointestinal tract due to the presence of b-glycosidic bonds, but subject to microbial
metabolism in the colon resulting in the release of the aglycone steviol which is then absorbed. In rats
and humans, steviol is further glucuronidated; steviol glucuronide is excreted with urine and faeces.
Two unpublished studies testing major and minor steviol glycosides in human faecal homogenate
have been provided by the applicant. Based on the results from unpublished and published studies,
the different rebaudiosides analysed share the same metabolic degradation (i.e. deglycosylation) by
the gut microbiome in the colon leading to the formation of steviol. Considering the data set, it can be
predicted that all 60 steviol glycosides considered in Appendix A follow the same metabolic fate in the
colon with an hydrolysation to steviol.
The Panel agreed that the overall metabolic fate of the steviol glycosides listed in Appendix A is the
same; therefore, it would be acceptable to use a read across approach taking the toxicological data
previously evaluated by EFSA, for the safety assessment of the 60 steviol glycosides and the ADI of
4 mg/kg bw per day will apply to all those steviol glycosides.
Regarding the genotoxicity, none of the submitted studies are considered adequate to assess the
genotoxic potential of the steviol glycosides preparations to be used as a food additive.
As part of the application dossier, the applicant has provided two published studies investigating the
effect of dietary administration of rebaudioside A and S. rebaudiana extract on reproductive organs.
Overall, in a study on ovarian function in rats with rebaudioside A, no effects were observed relevant
for hazard assessment. In addition, the study on sexual function in diabetic rats with a S. rebaudiana
extract cannot be used for hazard assessment.
The findings from the submitted genotoxicity studies and studies on reproductive organs and
related effects do not change the conclusions reached by the EFSA ANS Panel on genotoxicity and
reproductive toxicity when steviol glycosides were evaluated for their authorisation as a food additive
(EFSA ANS Panel, 2010). However, it is not possible to conclude if the mixture tested in all the various
genotoxicity studies previously evaluated by EFSA, can be considered to be sufficiently representative
of other kinds of mixtures that the proposed changes in the specifications would allow.
Overall, the Panel considered that read-across is justified and the list of 60 steviol glycosides listed
in Appendix A could provide a basis for an amendment of the specifications for steviol glycosides.
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However, the proposed change from 11 to 60 specified steviol glycosides, whilst maintaining the assay
value of not less than 95%, would allow less pure preparations of the food additive onto the market.
According to the proposed change in specifications, there remains a small but not insignificant fraction
of the additive that would be undefined and therefore cannot be evaluated by the Panel.
The Panel concluded that the inclusion of the 60 steviol glycosides in the proposed specifications
for steviol glycoside (E960) would not be of safety concern. However, the Panel cannot conclude on
the safety of the proposed amendment to the specifications of steviol glycosides (E 960) as food
additive if the purity assay value of not less than 95% for the total content of steviol glycosides is
maintained.
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1. Introduction
The present scientific opinion deals with the safety evaluation of a proposed modification of the EU
specifications of the already authorised food additive, steviol glycosides (E 960) to expand the list of
steviol glycosides to 60 steviol glycosides identified in the leaves of Stevia Rebaudiana Bertoni.
1.1. Background and Terms of Reference as provided by the European
Commission
1.1.1. Background
The use of food additives is regulated under the European Parliament and Council Regulation (EC)
No 1333/2008 on food additives.1 Only food additives that are included in the Union list, in particular
in Annex II to that regulation, may be placed on the market and used as in foods under the conditions
of use specified therein. Moreover, food additives shall comply with the specifications as referred to in
Article 14 of that Regulation and laid down in Commission Regulation (EU) No 231/2012.2
Steviol glycosides (E 960) is an authorised food additive in the European Union for use in several
food categories and specifications have been adopted for it. Presently, those specifications stipulate
steviol glycosides (E 960) as a final product containing not less than 95% of 11 identified steviol
glycosides - stevioside, rebaudiosides A, B, C, D, E, F, and M, steviolbioside, rubusoside and dulcoside
in any combination and ratio.
In 2017, the European Commission received a request vis-a-vis and amendment of the
specifications of steviol glycosides (E 960) to include all steviol glycosides identified in Stevia
rebaudiana Bertoni leaf extracts, including both “major” and “minor” glycosides, that may contribute to
the assay value of not less than 95% on a dried weight basis total steviol glycosides. The request was
assessed by EFSA (EFSA ANS Panel, 2018) which concluded that the submitted data were insufficient
to assess the safety of the proposed amendment of specifications.
In January 2019, the European Commission received an updated application containing additional
information, which according to the applicant, should address the concerns and questions raised in the
EFSA’s scientific opinion (EFSA ANS Panel, 2018).
1.1.2. Terms of Reference
The Commission requests the European Food Safety Authority to provide a scientific opinion on the
safety of the proposed amendment of the specifications of that food additive in accordance with the
Regulation (EC) No 1331/2008 establishing a common authorisation procedure for food additives, food
enzymes and food flavourings.
1.2. Information on existing authorisations and evaluations
Steviol glycosides (E 960) from water extraction of the leaves of the Stevia rebaudiana Bertoni
plant and described as ‘not less than 95% steviolbioside, rubusoside, dulcoside A, stevioside,
rebaudiosides A, B, C, D, E, F and M on the dried basis, in any combination and ratio’ is an authorised
food additive in the EU according to Regulation (EC) No 1333/2008 on food additives and
specifications have been defined in Commission Regulation (EU) No 231/2012.
The safety of steviol glycosides as a food additive was evaluated by EFSA in 2010 and an
acceptable daily intake (ADI) of 4 mg/kg body weight (bw) per day, expressed as steviol equivalents,
based on application of a 100-fold uncertainty factor to the no observed adverse effect level (NOAEL)
from a 2-year carcinogenicity study in the rat was established (EFSA ANS Panel, 2010). Following a
subsequent EFSA assessment in 2015 (EFSA ANS Panel, 2015a), rebaudioside D and M were included
in the specifications for steviol glycosides (E 960).
In 2019, the EFSA FAF Panel performed a safety evaluation for a modification of the specifications
following a new production process of steviol glycosides (E 960) (EFSA FAF Panel, 2019). The FAF
Panel concluded that there is no safety concern for Rebaudioside M produced via enzymatic
bioconversion, however recommended that the European Commission considers establishing separate
1 Regulation (EC) No 1333/2008 of the European Parliament and of the Council of 16 December 2008 on food additives. OJ L
354, 31.12.2008.
2 Commission Regulation (EU) No 231/2012 of 9 March 2012 laying down specifications for food additives listed in Annexes II
and III to Regulation (EC) no 1333/2008 of the European Parliament and of the Council. OJ L 83, 22.3.2012.
Proposed amendment of the specifications for steviol glycosides (E 960) as a food additive
www.efsa.europa.eu/efsajournal 6 EFSA Journal 2020;18(4):6106
specifications for Rebaudioside M produced via enzymatic bioconversion of purified stevia leaf extract
in Commission Regulation (EU) No 231/2012.
The Joint FAO/WHO Expert Committee on Food Additives (JECFA) established an ADI for steviol
glycosides of 4 mg/kg bw per day, expressed as steviol (JECFA, 2009).
In 2016, JECFA confirmed that rebaudioside A from multiple gene donors expressed in Yarrowia
lipolytica is included in the ADI of 4 mg/kg bw, expressed as steviol (JECFA, 2016). JECFA has
prepared new specifications for Rebaudioside A from Multiple Gene Donors Expressed in Yarrowia
lipolytica) for the yeast-derived product, recognising that it was manufactured by a distinctly different,
biosynthetic process compared with stevia leaf-derived products (JECFA, 2017).
JECFA recently issued new specifications for ‘Steviol Glycosides from Stevia rebaudiana Bertoni’ that
consist of a mixture of compounds containing a steviol backbone conjugated to any number or
combination of the principal sugar moieties (glucose, rhamnose, xylose, fructose and deoxyglucose) in
any of the orientations occurring in the leaves of S. rebaudiana Bertoni, provided that the total
percentage of steviol glycosides is not less than 95% (JECFA, 2017).
At the JECFA meeting in 2019, a framework was adopted for developing specifications for steviol
glycosides by four different methods of production (JECFA, 2019). Specifications for steviol glycosides
from Stevia Rebaudiana Bertoni obtained by water extraction were prepared (JECFA, 2020).
2. Data and methodologies
Data
The present evaluation is based on the data submitted in the application dossier (‘Documentation
provided to EFSA’ No 1) and additional information submitted by the applicant during the assessment
process following a request by EFSA (‘Documentation provided to EFSA’ No 2 and Documentation
provided to EFSA’ No 3).
Following the request for additional data sent by EFSA on 25 November 2019, the applicant
requested a clarification teleconference on 06 December 2020, after which the applicant provided
additional data on 03 January 2020.
Methodologies
This opinion was formulated following the principles described in the EFSA Guidance of the Scientific
Committee on transparency with regard to scientific aspects of risk assessment (EFSA Scientific
Committee, 2009) and following the relevant existing Guidances from the EFSA Scientific Committee.
The Guidance for submission for food additive evaluations in 2012 (EFSA ANS Panel, 2012) was
followed for the assessment.
3. Assessment
3.1. Technical data
3.1.1. Proposed identity of the food additive by the applicant
Specifications for steviol glycosides (E 960) have been defined in the Commission Regulation (EU)
No 231/2012. The current EU specifications for steviol glycosides (E 960) stipulate that a steviol
glycoside preparation must contain not less than 95% of 11 named steviol glycosides: stevioside,
rebaudiosides A, B, C, D, E, F and M, steviolbioside, rubusoside and dulcoside A.
According to the applicant, the stevia leaf extracts contain three groups of steviol glycosides which
they have described as: ‘major’ steviol glycosides for which commercial quantitative reference
standards are available; ‘minor’ steviol glycosides which are characterised compounds but for which
commercial quantitative reference standards are not available: and ‘related’ steviol glycosides which
contain the steviol backbone but for which complete structural elucidation has not been determined
(Documentation provided to EFSA No 2). The method of analysis including quantification is described
at Section 3.1.2 below. The ‘major’ and ‘minor’ steviol glycosides referred by the applicant are listed in
Appendix A.
The applicant asked to amend the existing EU specifications for steviol glycosides to allow for the
inclusion of 60 steviol glycosides identified in S. rebaudiana Bertoni leaves, including both ‘major’ and
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‘minor’ steviol glycosides, that may comprise the assay value of not less than 95% total steviol
glycosides (Appendix A).
The applicant stated that slight modifications can be applied at certain stages of the steviol
glycoside production processes (e.g. extraction, purification), while still adhering to the same general
manufacturing principles (hot water extraction of Stevia leaves followed by isolation and step-wise
purification using ion exchange resins and alcohol solvents). Therefore, it is possible to obtain steviol
glycoside preparations with higher levels of ‘minor’ steviol glycosides than the levels present in
currently available steviol glycoside products (Documentation provided to EFSA No 1). Steviol glycoside
mixtures with different ratios of steviol glycosides may be produced; the steviol glycoside distribution is
specific to each individual preparation and could contain any of the identified steviol glycosides (see
Appendix A) (Documentation provided to EFSA No 2).
According to the applicant, all steviol glycoside constituents are glycosylated derivatives of the
aglycone steviol and as such, all share the same backbone structure, differing only with respect to the
type and number of glycoside units (glucose, rhamnose, xylose, fructose, deoxyglucose, arabinose and
galactose) at positions R1 and R2 (Figure 1). Sixty steviol glycosides have been identified in
S. rebaudiana ranging from the lowest molecular weight (steviolmonoside, 481 g/mol) to the highest
one (rebaudioside IX, 1,778 g/mol) (See Appendix A). Steviol glycosides were isolated from different
steviol glycoside extracts after several extraction and crystallisation steps; not every stevia leaf extract
may contain all of the steviol glycosides in measurable quantities.
3.1.2. Specifications
According to the applicant (Documentation provided to EFSA n. 1), steviol glycosides are
completely hydrolysed to steviol in the intestine at generally similar rates and, therefore, the necessity
for steviol glycoside preparations from S rebaudiana Bertoni to be comprised of specific individual
steviol glycoside is no longer relevant. The following three changes to the EU specifications for E 960
steviol glycosides are proposed by the applicant (see Appendix B):
• The definition of steviol glycosides be expanded to include 60 steviol glycosides identified in
S. rebaudiana Bertoni leaves (conjugated with glucose, rhamnose, xylose, fructose, deoxyglucose,
arabinose and galactose) that may comprise the assay value of not less than 95%;
• The listing of the chemical names, molecular formulas, molecular weights and Chemical
Abstracts Service (CAS) numbers for individual steviol glycosides be replaced with 1 structural
formula depicting the steviol backbone with R1 and R2 groups that ‘can be 1 or more sugar
moieties, including glucose, rhamnose, xylose, fructose, deoxyglucose, arabinose, and
galactose’, as listed in Appendix A in this opinion;
• Microbiological parameters be added to the specification as follows: Total (aerobic) plate count –
not more than 1,000 CFU/g; Yeasts and moulds – not more than 200 CFU/g; E. coli – negative in
1 g; Salmonella – negative in 25 g.
According to the applicant (Documentation provided to EFSA n. 3), the current EU specification of
steviol glycosides specifies that the purity of the leaf extract should be no less than 95% of the 11
named glycosides. The specifications also lists total ash < 1%, loss of drying < 6% and residual
solvents, methanol < 0.2% and ethanol < 0.5%. Adding the ash and residual solvents together with
the major and minor steviol glycosides, the total composition gets close to 100%. The difference
between the estimated composition and 100% is mainly contributed by related glycosides. Therefore,










Figure 1: Structure of the steviol backbone
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According to the applicant, the additive may contain residues of processing aid used in the
manufacturing process. Several other related steviol glycosides that may be present in the Stevia
rebaudiana plant or generated as a result of the production process, have been identified in small
amounts (0.1–2.0% w/w) (Appendix B).
The Panel noted that even allowing for the presence of ash, residuals solvents and residues of
processing aids and these other related glycosides, the proposed specification value of 95% still gives
room for an appreciable unknown fraction.
Regarding toxic elements, in addition to the maximum limits for lead and arsenic already included
in the current EU specifications for E 960, results for the analysis of cadmium and mercury were also
reported (< 0.005 mg/kg for cadmium and mercury). Based on the analytical data provided, the
Panel noted that maximum limits for cadmium and mercury should be added to the proposed
specifications. Additionally, lower levels of the maximum limits for lead and arsenic could be considered
in the proposed specifications since the results obtained in the five batches analysed
were < 0.011 mg/kg for arsenic and < 0.42 mg/kg for lead.
In view of the botanical origin of the stevia, limits for the presence of pesticides should be
considered. The same samples as were tested for toxic elements were subjected to a multiresidue
pesticide screen that covered a range of commonly used pesticides. No pesticide residues were
detected in any of the finished samples. The Panel noted that MRLs for pesticides set under Regulation
(EC) 396/20053 apply to stevia (Stevia rebaudiana) as listed in Part B of Annex I. For processed
products derived from stevia, the provisions of Article 20 are applicable, meaning that the changes in
the levels of pesticide residues caused by processing need to be taken into account.
No information was provided by the applicant on particle size of the product in powder form.
With regard to a method of analysis, the applicant described an HPLC/UV assay in tandem with MS
detection. By this method, steviol glycoside extract preparations can be assayed for ‘major’ and ‘minor’
steviol glycosides, including compounds for which commercial quantitative reference standards are not
presently available, to determine the total steviol glycoside content. The principle of the methods is the
same as those described in the JECFA monograph (JECFA, 2017), whereby the 13 major steviol
glycosides can be separated and quantified by a validated HPLC/UV method against the available
glycoside standards. The remaining minor steviol glycosides are identified by HPLC/UV/MS, and the
concentration of each of them is calculated using their HPLC-UV peak area, corrected for the molecular
mass of the minor glycoside ratioed to the molecular mass of rebaudioside A (967 amu), and the
rebaudioside A UV standard curve.
Information on the composition of two representative steviol glycosides preparations that do not
meet the current EU specifications was provided. The content of the 11 steviol glycosides recognised
in the EU specifications is below 95%, however, if the content of rebaudioside N, rebaudioside O and
other ‘minor’ steviol glycosides are included in the assay value, then the total steviol glycoside content
is above the 95% limit value.
3.1.3. Manufacturing process
The crushed Stevia leaves are extracted with hot water and the resulting extract is subjected to
isolation and purification steps (by use of ion exchange resins and alcohol solvents (methanol and/or
ethanol)). It is recognised that slight modifications can be applied at certain stages of the production
process (e.g. extraction, purification), while still adhering to the same general principles, to obtain
steviol glycoside preparations with specific distributions of individual steviol glycosides (‘major’ and
‘minor’). In particular, the adsorption column system contains different sections that adsorb different
proportions of the various steviol glycosides from a mixture. Because these different sections are
desorbed separately with solvent(s), steviol glycoside mixtures with different ratios of individual steviol
glycosides may be produced simultaneously. This initial stage is followed by additional purification
steps, including further and repeated recrystallisation and separation steps. The production process
involves the use of other processing aids, calcium hydroxide as a flocculant and activated carbon as
decolourising agent. This process results in a preparation that contains 95% total steviol glycosides
(Documentation provided to EFSA No.1).
3 Regulation (EC) No 396/2005 of the European Parliament and of the Council of 23 February 2005 on maximum residue levels
of pesticides in or on food and feed of plant and animal origin and amending Council Directive 91/414/EEC. OJ L 70,
16.3.2005.
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3.1.4. Methods of analysis in food
No method of analysis of steviol glycosides in foods was provided.
3.1.5. Stability of the substance, and reaction and fate in food
A pH stability test with two steviol glycosides mixtures (one with > 50% Reb A and another with Reb
D (55–68%) and Reb M (17–27%)) at different temperatures (5–56°C) was provided. The degradation
was observed at pH 2 at temperature above 25°C and at pH 3–8 at 56°C. Steviol glycosides mixture
(> 50% Reb A) in powder was found to be stable during 122 weeks storage in glass amber bottles at
40°C.
According to the applicant: ‘stability data for rebaudioside A and stevioside in food matrices can be
extrapolated to steviol glycosides in general, and the conclusions regarding the stability of steviol
glycosides made by EFSA and other scientific bodies (that steviol glycosides are thermally and
hydrolytically stable for use in foods and acidic beverages under normal processing and storage
conditions) can be extended to include the “major” and “minor” steviol glycosides present in the steviol
glycoside mixtures that are the subject of this safety assessment’. Based on the structural similarities
between steviol glycosides, the Panel agreed that the stability findings previously evaluated (EFSA,
2010) can be extrapolated to include the major and the minor steviol glycosides as suggested by the
applicant.
3.2. Proposed uses and use levels
Maximum level of steviol glycosides (E 960) expressed as steviol equivalents are defined in Annex II
to Regulation (EC) No 1333/2008.1
The proposed amendment to expand the definition of steviol glycosides to include all those
identified in the extracts from the Stevia Rebaudiana plant is proposed for use as high-intensity
sweetener in food and beverages under the same conditions as those already approved for steviol
glycosides (E 960) in the EU (Regulation (EC) No 1333/2008) (Documentation provided to EFSA n. 1).
3.3. Exposure data
Because the proposed uses and use levels for the proposed amendment to expand the definition of
steviol glycosides to include all those identified in the extracts from the Stevia Rebaudiana plant are
the same as the already authorised food additive steviol glycosides (E 960), the applicant did not
provide an exposure estimate but made reference to the latest estimated exposure to E 960 (e.g.
EFSA ANS Panel, 2015b).
The Panel considers that if steviol glycosides would be replaced by steviol glycosides mixture
containing both ‘major’ and ‘minor’ steviol glycosides, exposure to steviol glycosides mixture
(expressed as steviol equivalent) will not be higher than the last EFSA estimate of exposure to steviol
glycosides (E 960) (EFSA ANS Panel, 2015b).
3.4. Biological and Toxicological data
Within the application dossier, scientific publications considered by the applicant relevant to the
safety assessment of steviol glycosides were submitted.
The present evaluation will focus on existing and new data provided by the applicant on the rates
of in vitro hydrolysis of ‘major’ and ‘minor’ steviol glycosides by pooled faecal homogenates from
human volunteers.
Only toxicological studies with steviol glycosides not previously evaluated by EFSA have been
considered in the current assessment by the Panel.
3.4.1. Absorption, distribution, metabolism and excretion
Data on ADME of some of steviol glycosides currently listed in the EU specifications have been
considered and summarised in previous EFSA opinions (EFSA ANS Panel, 2010, 2015a). According to
these opinions, stevioside and Rebaudioside A are not hydrolysed by digestive enzymes of the upper
gastrointestinal tract due to the presence of b-glycosidic bonds. After entering the colon intact, these
two steviol glycosides are subject to microbial degradation by the gut microbiome, resulting in the
release of the aglycone steviol which is then absorbed. In rats and humans, absorbed steviol is
glucuronidated; steviol glucuronide is then excreted in the urine and faeces.
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The microbial hydrolysis of different steviol glycosides, in particular rebaudioside A, B, C, D, E, F, M,
steviolbioside and stevioside (with different purity levels or purity not specified) has been investigated
in vitro with human faecal incubations.
Summary of published studies submitted by the applicant
Published ADME studies testing different steviol glycosides have been considered. A tabulated
summary of these studies is available in Appendix C. These are in vivo studies in both rats and
humans with oral administration of rebaudioside A or stevioside.
In vivo rat studies analysed the levels of steviol, rebaudioside A and stevioside in blood, urine,
faeces and organs. These studies showed that rebaudioside A and stevioside are metabolised in the
lower gut by gut microbioma and do not accumulate in the organs (Wingard et al., 1980; Nakayama
et al., 1986; Roberts and Renwick, 2008; Roberts et al., 2016).
Human in vivo studies with stevioside and rebaudioside A confirmed that both products are
degraded to steviol by gut microbioma (Simonetti et al., 2004; Geuns et al., 2006; Wheeler et al.,
2008). One in vivo study investigated the kinetic of stevioside in human and showed that the final
metabolite steviol reaches the Cmax between 19 and 20 h post-administration and is not detectable in
blood at 48 h post-dose (Roberts et al., 2016). The results of these studies showed clear similarities in
metabolic disposition between rat and human.
In vitro studies with human faecal homogenates showed that different rebaudiosides shared the
same metabolic fate with a complete hydrolysis to steviol (Koyama et al., 2003; Purkayastha et al.,
2014, 2015, 2016). The rate of degradation varies to some extent with the number and type of
sugars bound to the steviol aglycone structure. Rebaudioside A has the fastest hydrolysation rate
and rebaudioside F has the slowest rate (Purkayastha et al., 2016). One early in vitro study with rat
caecal bacterial cells with rebaudioside A confirmed the degradation of rebaudioside A to steviol
(Wingard et al., 1980). One study investigated the metabolism of stevia mixture (rebaudioside A,
stevioside, rebaudioside C and Dulcoside A) and a mixture of enzymatically modified stevia
(a-monoglucosylrebaudioside A-1, a-monoglucosylrebaudioside A-2, a-monoglucosylrebaudioside A-3,
a-monoglucosylstevioside-1, a-monoglucosylstevioside-2 and a-diglucosylstevioside) in faecal
homogenate. This study showed that rebaudioside A, stevioside, a-monoglucosylrebaudioside A and a-
monoglucosylstevioside are deglycosylated first and then hydrolysed to steviol (Koyama et al., 2003).
The Panel noted that the steviol glycosides tested (A, B, C, D, E, F, M, steviobioside and stevioside)
are already authorised and were previously assessed by EFSA (EFSA ANS Panel, 2010, 2015a,b).
Additional unpublished in vitro studies submitted by the applicant
A mixture of steviol glycosides (RAF) composed by 7% w/w rebaudioside A and 93% w/w
fructosylated rebaudioside A has been tested in human faecal homogenate samples (BRI, 2015
Documentation provided to EFSA N.1). RAF (0.2 mg/mL) were incubated with male and female faecal
homogenate samples under anaerobic conditions at 37°C for 4–48 h. Liquid chromatography-mass
spectrometry (LC/MS) was used to measure the rate of formation and amount of steviol generated
from the microbial hydrolysis. Rebaudioside A and fructosylated rebaudioside A were completely
metabolised to steviol after both 24- and 48-hours incubation.
A subsequent in vitro metabolic study in human faecal homogenate samples has been performed
with a mixture of steviol glycoside A95 or a mixture of minor steviol glycosides (rebaudioside AM, W2,
Y, U2, V N and O) over an incubation period of 72 h (BRI, 2018 Documentation provided to EFSA N.1).
Steviol glycoside A95 is a mixture of 13 different steviol glycosides with the main components being
rebaudioside D and M (58 and 21%, respectively). Other steviol glycosides such as rebaudioside A, B,
C, E, F, O, N and stevioside are present in low percentage. Steviol glycoside A95 was incubated in faecal
homogenates of adult male, adult female and paediatric samples at a concentration of 0.2 mg/mL
under anaerobic conditions at 37°C for between 4 and 72 h. The steviol glycoside mixture prepared
with minor steviol glycosides was incubated with adult male and adult female pooled faecal
homogenate samples at concentrations of 0.2 and 0.4 mg/mL under anaerobic conditions at 37°C for
4–48 h. Liquid chromatography-mass spectrometry (LC/MS) analysis was used to provide metabolic
mass balance on the molar equivalent formation of the steviol metabolite over the time course.
Rebaudioside M and D present in steviol glycoside A95 deglucosylated to steviol over the first 12 hours
in both adult and paediatric samples. Individual minor steviol glycosides (Reb AM, W2, Y, U2, V, N and
O) showed also a deglucosylation to steviol within 12 hours of incubation in adult samples. Differences
in the rate of degradation were observed among major steviol glycosides A95 with the rebaudioside M
and D showing an almost complete deglucosylation at the 12-hour time point. Among the minor steviol
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glycosides rebaudiosides AM and O had the quickest rate of degradation with a detected concentration
of approximately 50% detected at the 4-hour time point and almost complete deglucosylation at the
12 h. Samples from female adults showed a more rapid degradation compared to male adult samples
for rebaudioside AM, N and O.
In vitro metabolism studies demonstrated that major and minor steviol glycosides are extensively
metabolised to steviol within 12 h. The data also confirm similar degradation rates between gender
and between adults and children, except for rebaudioside AM, N and O for which a more rapid
degradation has been measured in the female adult samples. The Panel noted that some ‘minor’
glycosides have been tested only in one in vitro metabolic study (BRI, 2018 Documentation provided
to EFSA N.2).
Based on available knowledge, the Panel noted steviol glycosides with b-glycosidic bonds are not
hydrolysed by digestive enzymes of the upper gastrointestinal tract but subject to microbial
metabolism in the colon. Considering the data set, it can be presumed that all 60 steviol glycosides
considered in Appendix A follow the same metabolic fate in the colon with an hydrolysation to steviol.
Some minor differences in degradation rate can be anticipated depending on the number and type of
sugar moieties bound to the steviol (aglycone).
3.4.2. Acute toxicity
No new acute toxicity studies were provided.
3.4.3. Short-term and subchronic toxicity
No new short-term or subchronic toxicity studies were provided.
3.4.4. Genotoxicity
Sharif and co-workers investigated the genotoxic potential of stevioside in CCD18Co myofibroblasts
and human HCT116 cells using the in vitro alkaline comet assay (Sharif et al., 2017). A single
concentration (200 lM) was tested and no information on the composition and the purity of the test
item was provided. The authors concluded that the test item did not exhibit genotoxic effects.
Considering that the testing method used is not validated for regulatory purposes and the nature of
the test item is not clear, this study could not be used for the assessment of genotoxicity.
The genotoxic potential of stevia was evaluated using in vitro micronucleus and chromosomal
aberration tests in human lymphocytes (Ucar et al., 2018). In both the assays, the test item (stevia
extract, no further information on steviol glycoside composition) was added up to a concentration of
16 lg/mL, 24 and 48 h after the culture initiation and cells were harvested after 72 h. The range of
the concentration used was chosen on the basis of the ADI, with the maximum concentration
corresponding to 49 ADI. No significant increases in the number of chromosomal aberrations or
micronuclei were reported at any stevia test concentration when compared to the negative control.
The Panel noted that the experimental conditions used in this study do not meet the recommendations
of the OECD test guidelines 473 and 487. In particular: (i) the tests were conducted only in the
absence of metabolic activation; (ii) the treatment timings used for both the assays were different
from the indications of the OECD guidelines; (iii) the tested concentrations were chosen on the basis
of the ADI rather than considering the cytotoxicity of the treatment; (iv) the cytotoxicity of the
treatment was not reported. Moreover, the information provided on the test item are not sufficient to
clarify if it is representative of the additive under evaluation. Overall, also these tests cannot be
considered suitable to assess the genotoxic potential of the stevioside.
A third experimental study (Zhang et al., 2017) submitted by the applicant included three different
assays conducted with an ethanolic extract of S. rebaudiana Bertoni leaves: a bacterial reverse
mutation assay, an in vivo micronucleus and a mouse sperm malformation assay.
1) The bacterial reverse mutation assay was conducted in S. typhimurium TA97, TA98, TA100,
and TA102, exposed to concentrations of up to 5,000 lg/plate of stevia extract in the
presence or absence of metabolic activation. No increase in the number of revertants was
observed in any experimental condition. This test was conducted in line with the OECD test
guideline 471, except that the strain TA1535 was not included in the strain battery.
2) In the in vivo micronucleus assay, the animals (Kunming mice, 5/sex per group) were
administered the test item by oral gavage at doses up to 10,000 mg/kg bw twice at a 24-h
interval. For each animal, 200 red blood cells and 1000 polychromatic erythrocytes (PCE)
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were observed to determine the proportion of PCE and incidence of micronuclei. No
mutagenic effect was reported at any dose evaluated. However, no evidence of target cells
exposure (alteration of NCE/PCE ratio) was provided; therefore, the study should be
considered inconclusive.
3) The mouse sperm malformation assay is based on a morphological evaluation of the
treatment effect on spermatozoa: it is not a genotoxicity test and it is not validated for any
endpoint relevant to regulatory toxicology.
Also, in these tests, the information provided on the test item are not sufficient to clarify if it is
representative of the additive under evaluation.
3.4.5. Chronic toxicity and carcinogenicity
No new chronic toxicity or carcinogenicity studies were available.
3.4.6. Studies on reproductive organs and related effects
As part of the application dossier, the applicant has provided the published studies Jiang et al.
(2018) and Ghaheri et al. (2018) investigating the effect of dietary administration of rebaudioside A
and S. rebaudiana extract on reproductive organs.
The potential effect of rebaudioside A on ovary function in rats was investigated by Jiang et al. (2018).
Rebaudioside A was provided in drinking water to weanling Sprague-Dawley rats (n = 6 females/group)
for a total of 48 days at dose levels of 0, 0.5 or 2.5 mM (equal to 0, 210 or 1,430 mg/kg bw per day).
Food and water were provided ad libitum. In the high-dose group, body weight was significantly
decreased from day 18 to 30 of the study; however, at the end of the study, no significant difference in
body weight between the high-dose rebaudioside A and control groups was observed. Water
consumption was significantly increased in the high-dose group during the entire study period, while
the low-dose group was reported to be notably different from the control group after 21 days of
treatment. Furthermore, the high-dose group water consumption was reported to be remarkable
higher than the low-dose group in the last 3 weeks of treatment. Conversely, rebaudioside A was not
reported to influence food intake in either group. No significant differences between the control and
test article treated groups were reported for puberty onset (vaginal opening) or body weights at
puberty, nor were differences in oestrous cycles observed. No morphological changes in the ovaries of
the rebaudioside A treated groups were reported. Serum levels of progesterone in the rebaudioside A
groups were significantly decreased compared to the control group and decreased expression of 3b-
hydroxysteroid dehydrogenase, an enzyme involved in progesterone synthesis, was measured in the
ovaries via Western blotting. Several other steroidogenesis-related factors were also reported to
decrease based on the Western blot results; however, the significance of these findings with respect to
safety is limited as no effects on ovarian morphology or oestrous cyclicity were reported following
rebaudioside A exposure for 48 days. The Panel concluded that no clearly adverse effects were
observed in the study.
Ghaheri et al. (2018) investigated the effects of an aqueous S. rebaudiana extract on reproduction
function in diabetes-induced healthy adult male albino rats of Wistar strain. Diabetes mellitus was
induced in healthy rats via intraperitoneal injection of 50 mg streptozotocin/kg bw. The rats that
reached fasting glucose levels greater than 250 mg/dL after 72 hours were selected for the study.
Animals (n = 7/group) were administered stevia extract at doses of 5, 50 or 100 mg/kg bw per day by
gavage for 28 days. A diabetic and non-diabetic control group received 2 mL distilled water only.
Sexual behaviours of the rats were recorded for 30 minutes every 2 weeks for 1 month, including
mount latency, intromission latency, mount frequency, intromission frequency, ejaculation latency, the
mount latency post ejaculation and ejaculation frequency. Following the study period, animals were
killed, and serum concentration of testosterone was measured. Histological examination was carried
out on the right testis and epididymis. In diabetic rats, a significant increase in the frequency of
intromission was observed in the low-dose group, compared to diabetic control rats. In addition,
diabetic rats of the low-dose group showed a significant increase in the frequency of ejaculation,
compared to the diabetic control and high-dose animals. However, a significant decrease in the latency
of ejaculation was observed in the low-dose group when compared to the high-dose animals, although
the effect was not significant between the treated animals and the controls. Significant differences in
other sexual behaviour parameters measured were not observed in the animals. Furthermore, a
significant reduction in the number of Leydig cells in high-dose animals was noted, compared to the
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non-diabetic control group; however, this effect was not significantly different compared to the diabetic
control rats. Relative testis and epididymides weights and serum testosterone levels showed no
significant differences among the study animals. Based on the results of the study, the authors
concluded that there is no risk related to reproductive parameters following consumption of stevia. The
Panel noted that this study did not report results relevant for hazard assessment.
Overall, in a study on ovarian function in rats with rebaudioside A, no effects were observed
relevant for hazard assessment. In addition, the study on sexual function in diabetic rats with a
S. rebaudiana extract cannot be used for hazard assessment.
3.4.7. Hypersensitivity, allergenicity and food intolerance
In vivo and in vitro effects of stevioside (>95% purity) on the release of cytokines tumour necrosis
factor (TNF-a) and interleukin (IL-1b) from isolated rat peripheral blood mononuclear cells (PBMCs) and
presence in the plasma was investigated in rats (Noosud et al., 2017). Stevioside was administered via
oral gavage to male Wistar rats (n = 6/group) at doses of 0, 500 and 1000 mg/kg bw per day over a
period of 6 weeks. PBMCs were stimulated with and without lipopolysaccharide (LPS) in vitro for
24 hours to induce cytokine production. Oral administration of stevioside did not show any toxicity in
PBMCs, and at the end of treatment period, the plasma levels of TNF-a and IL-1b were not detectable in
plasma. In stevioside-fed animals, the levels of TNF-a in LPS-stimulated PBMCs were significantly
decreased compared to the control group. Results of this study demonstrated that oral ingestion of
stevioside inhibits the formation of inflammatory cytokines TNF-a and IL-1b in rats at high doses.
The Panel noted that no conclusion on hypersensitivity and allergenicity can be drawn from this
study.
3.4.8. Human studies
Human studies performed with commercially available products containing Stevia or stevia extract
were submitted within the application dossier (Kassi et al., 2016; Ritu and Nandini, 2016; Shin et al.,
2016; Al-Dujaili et al., 2017; Ahmad et al., 2018a; Rizwan et al., 2018). The Panel noted that the
purpose of these studies was to investigate the efficacy of product containing stevia on the glucose
handling and insulin levels. The Panel noted that substances tested in these studies were not fully
characterised and represent samples of commercially available stevia derivatives. None of the studies
provided information that was considered relevant for the current assessment.
3.4.9. Other studies
The applicant has provided studies investigating potential mechanisms of action of steviol
glycosides (Akbarzadeh et al., 2015; Holvoet et al., 2015; Abo Elnaga et al., 2016; Aranda-Gonzalez
et al., 2016; Assaei et al., 2016; Perumal et al., 2016; Elzinga et al., 2017; Philippaert et al., 2017;
Potocnjak et al., 2017; Reynolds IV et al., 2017; Ilic et al., 2017; Ahmad and Ahmad, 2018; Ahmad
et al., 2018a; Barrios-Correa et al., 2018). The Panel noted that these studies have been performed
with extract prepared in the laboratory and for which the composition is unknown or based on
rebaudioside A or stevioside in isolation. None of the studies provided information that was considered
relevant for the current assessment.
3.5. Discussion
According to the applicant, steviol glycosides are completely hydrolysed to steviol in the intestine at
generally similar rates and, therefore, the necessity for steviol glycosides preparations from
S. rebaudiana Bertoni to be comprised of specific individual steviol glycoside is no longer relevant.
Therefore, to reiterate, the following three changes to the EU specifications for E 960 steviol glycosides
were proposed by the applicant:
• The definition of steviol glycosides be expanded to include 60 steviol glycosides identified in
S. rebaudiana Bertoni leaves (conjugated with glucose, rhamnose, xylose, fructose,
deoxyglucose, arabinose and galactose) as listed in Appendix A that may comprise the assay
value of not less than 95%;
• The listing of the chemical names, molecular formulas, molecular weights and Chemical
Abstracts Service (CAS) numbers for individual steviol glycosides be replaced with one
structural formula depicting the steviol backbone with R1 and R2 groups that ‘can be 1 or
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more sugar moieties, including glucose, rhamnose, xylose, fructose, deoxyglucose, arabinose,
and galactose’, as listed in Appendix A in this opinion;
• Microbiological parameters be added to the specifications.
Regarding the proposal from the applicant to expand the definition of food additive E960 to include
60 steviol glycosides identified in S. rebaudiana Bertoni leaves in the assay value of not less than 95%,
the Panel noted that this proposal would allow to have commercial products of lower purity than is
currently the case. With the existing specifications, the food additive must be comprised of not less
than 95% of the 11 named steviol glycosides. These specifications have an inbuilt degree of
conservatism concerning the possible presence of impurities. In current commercial products, the
remaining 5% of non-defined material will in fact be made up (in-part or even largely) of other minor
and related steviol glycosides. The proposed change is to include all 60 steviol glycosides (major and
minor steviol glycosides) in the same limit value of 95%, when in the current EU specifications, only
major steviol glycosides (11 named steviol glycosides) are included in the 95%, and this would permit
the presence of up to 5% of impurities. The Panel noted that even taking into account the presence of
ash, residuals solvents and residues of processing aids and the other related steviol glycosides, the
proposed specification value of 95% still gives room for an appreciable unknown fraction. Taking into
account the data submitted in the application dossier, the Panel noted that it is technically possible to
manufacture steviol glycosides (E960) with a purity higher than 95% for the total steviol glycosides. In
the absence of a higher purity assay value, the Panel considered that identity and quantity of the
impurities in the proposed specifications of steviol glycosides (E 960) should be better defined to
ensure that an assay value of not less than 95% for the total content of steviol glycosides would not
be of safety concern.
The Panel noted and supported the proposal made by the applicant for amending the specifications
with the inclusion of a generic backbone structure and a reference to the 60 steviol glycosides listed in
Appendix A.
The Panel agreed with the proposal from the applicant to include microbiological criteria in the EU
specifications.
Regarding toxic elements, in addition to the maximum limits for lead and arsenic already included
in the current EU specifications for E 960, results for the analysis of cadmium and mercury were also
reported by the applicant (< 0.005 mg/kg for cadmium and mercury). Based on the analytical data
provided, the Panel noted that maximum limits for cadmium and mercury should be added to the
proposed specifications. Additionally, lower levels of the maximum limits for lead and arsenic could be
considered in the proposed specifications since the results obtained in the five batches analysed were
< 0.011 mg/kg for arsenic and < 0.42 mg/kg for lead.
Data on ADME of some of steviol glycosides currently listed in the EU specifications have been
considered and summarised in previous EFSA opinions (EFSA ANS Panel, 2010, 2015a). Based on the
available data set, stevioside and Rebaudioside A are not hydrolysed by digestive enzymes of the
upper gastrointestinal tract due to the presence of b-glycosidic bonds, but subject to microbial
metabolism in the colon resulting in the release of the aglycone steviol which is then absorbed. In rats
and humans, steviol is further glucuronidated; steviol glucuronide is excreted with urine and faeces.
Two unpublished studies testing major and minor steviol glycosides in human faecal homogenate
have been provided by the applicant. Based on the results from unpublished and published studies,
the different rebaudiosides analysed share the same metabolic degradation (i.e. deglycosylation) by
the gut microbiome in the colon leading to the formation of steviol. Some minor differences in
degradation rate can be anticipated depending on the number and type of sugar moieties bound to
the steviol (aglycone). Yet, given the variations of metabolic rates in the reported studies and
considering anticipated human exposure levels, the observed differences are not large enough to rebut
the concept of similar metabolic rates of various steviol glycosides. Considering the data set, it can be
presumed that all 60 steviol glycosides considered in Appendix A follow the same metabolic fate in the
colon with an hydrolysation to steviol.
The Panel agreed that the overall metabolic fate of the steviol glycosides listed in Appendix A is the
same; therefore, it would be acceptable to use a read-across approach taking the toxicological data
previously evaluated by EFSA, for the safety assessment of the 60 steviol glycosides and the ADI of
4 mg/kg bw per day will apply to all those steviol glycosides.
In none of the submitted genotoxicity studies, it was possible to ascertain if the test item is
representative of the additive under evaluation. Moreover, in the study by Sharif et al., 2017, a testing
method not validated for risk assessment was used; the study by Ucar et al., 2018 was not conducted in
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line with the current scientific standard and in compliance with the OECD test guidelines; in the study by
Zhang et al., 2017, the Ames test was not conducted on all the bacterial strains that are recommended by
the relevant OECD guideline and the in vivo micronucleus was inconclusive (negative, but without
evidence of target exposure). Overall, none of the submitted studies are considered adequate to assess
the genotoxic potential of the steviol glycosides preparations to be used as a food additive.
The findings from the submitted genotoxicity studies (Sharif et al., 2017; Zhang et al., 2017) and
studies on reproductive organs and related effects (Ghaheri et al., 2018; Jiang et al., 2018) do not
change the conclusions reached by the EFSA ANS Panel on genotoxicity and reproductive toxicity when
steviol glycosides were evaluated for their authorisation as a food additive (EFSA ANS Panel, 2010).
However, it is not possible to conclude if the mixture tested in all the various genotoxicity studies
previously evaluated by EFSA, can be considered to be sufficiently representative of other kinds of
mixtures that the proposed changes in the specifications would allow. For the particular mixtures that
the applicant characterised and provided assay data on, this would not necessarily be a concern
because the sum of all steviol glycosides (major, minor and related) can approach 100%. However, in
a generic authorisation procedure used by European Commission, other products and other producers
have to be anticipated as well. The proposed amendment of the specifications could result in a higher
fraction of impurities; therefore, characterisation of the nature and amount of the various impurities
would be required.
Overall, the Panel considered that read-across is justified and the list of 60 steviol glycosides listed
in Appendix A could provide a basis for an amendment of the specifications for steviol glycosides.
However, the proposed change from 11 to 60 specified SGs, whilst maintaining the assay value of not
less than 95%, would allow less pure preparations of the food additive onto the market. According to
the proposed change in specifications, there remains a small but not insignificant fraction of the
additive that would be undefined and therefore cannot be evaluated by the Panel. For these reasons,
the Panel cannot conclude on the safety of the proposed amendment of the specifications for steviol
glycosides (E 960).
4. Conclusions
The Panel concluded that the inclusion of the 60 steviol glycosides in the proposed specifications
for steviol glycoside (E960) would not be of safety concern. However, the Panel cannot conclude on
the safety of the proposed amendment to the specifications of steviol glycosides (E 960) as food
additive if the purity assay value of not less than 95% for the total content of steviol glycosides is
maintained.
Taking into account the data submitted in the application dossier, the Panel noted that it is
technically possible to manufacture steviol glycosides (E960) with a purity higher than 95% for the
total steviol glycosides.
Documentation provided to EFSA
1 Dossier “Application for a change in the steviol glycoside specification to expand the list of
steviol glycosides in the European Union to all those identified in the leaves of Stevia
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2 Additional information on 27 December 2019. Submitted by PureCircle Limited in response to
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3 Additional information on 10 February 2020. Submitted by PureCircle Limited in response to a
request from EFSA.
4 BRI Report no. RPT-PUR-2015-001, 2015. Pilot In Vitro Metabolism of RAF in Male and Female
Pooled Human Intestinal Fecal Homogenates Under Physiological Anaerobic
Conditions.Unpublished report. Submitted within the application dossier. Submitted within the
application dossier.
5 BRI Report no. RPT-PUR-2018-001, 2018. In Vitro Anaerobic Metabolism of Steviol Glycosides
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ADI acceptable daily intake
ANS EFSA Panel on Food Additives and Nutrient Sources added to Food
BIOHAZ EFSA Panel on Biological Hazards
bw body weight
CAS Chemical Abstracts Service
CFU colony forming units
FAF EFSA Panel on Food Additives and Flavourings
FAO Food and Agriculture Organisation
FEEDAP EFSA Panel on Additives and Products or Substances used in Animal Feed
HPLC high-performance liquid chromatography
IL-1b interleukin
JECFA Joint FAO/WHO Expert Committee on Food Additives
LC/MS liquid chromatography–mass spectrometry
NOAEL no observed adverse effect level
PBMCs peripheral blood mononuclear cells
PCE polychromatic erythrocytes
TNF-a tumour necrosis factor
WHO World Health Organization
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Appendix A – Summary of trivial formula, CAS Number, molecular weight, steviol equivalent and R-group (from
Figure 1) of identified steviol glycosides from the leaves of Stevia rebaudiana Bertoni (Documentation provided to
EFSA No 2)
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Appendix B – Proposed specifications for Steviol Glycosides (E960) (Documentation provided to EFSA n. 5)
Steviol glycosides (E 960)
Commission Regulation 231/2012
Proposed specifications for E 960 Steviol
(Documentation provided to EFSA n. 1)
Definition The manufacturing process comprises two main phases: the first involving water extraction of
the leaves of the Stevia rebaudiana Bertoni plant and preliminary purification of the extract by
employing ion exchange chromatography to yield a steviol glycoside primary extract, and the
second involving recrystallisation of the steviol glycosides from methanol or aqueous ethanol
resulting in a final product containing not less than 95% of the below identified 11 related
steviol glycosides, in any combination and ratio. The additive may contain residues of ion-
exchange resins used in the manufacturing process. Several other related steviol glycosides
that may be generated as a result of the production process, but do not occur naturally in the
Stevia rebaudiana plant have been identified in small amounts (0.10 to 0.37% w/w).
Steviol glycosides consists of a mixture of compounds
containing a steviol backbone conjugated to any number
or combination of the principal sugar moieties (glucose,
rhamnose, xylose, fructose, arabinose, galactose and
deoxyglucose) in any of the orientations occurring in the
leaves of Stevia rebaudiana Bertoni as listed in
Appendix A. The product is obtained from the leaves of
Stevia rebaudiana Bertoni. The leaves are extracted with
hot water and the aqueous extract is passed through an
adsorption resin to trap and concentrate the component
steviol glycosides. The resin is washed with a solvent
alcohol to release the glycosides and product is
recrystallised from methanol or aqueous ethanol. Ion
exchange resins may be used in the purification process.
The final product may be spray-dried.
The additive may contain residues of processing aid
used in the manufacturing process. Several other related
steviol glycosides that may be present in the Stevia
rebaudiana plant or generated as a result of the
production process, have been identified in small
amounts (0.1 to 2.0% w/w).
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Steviol glycosides (E 960)
Commission Regulation 231/2012
Proposed specifications for E 960 Steviol
(Documentation provided to EFSA n. 1)
Chemical name Steviolbioside: 13-[(2-O-b-D-glucopyranosyl-b-D-glucopyranosyl)oxy]kaur-16-en-18-oic acid
Rubusoside: 13-b-D-glucopyranosyloxykaur-16-en-18-oic acid, b-D-glucopyranosyl ester
Dulcoside A: 13-[(2-O-a–L-rhamnopyranosyl-b–D-glucopyranosyl)oxy]kaur-16-en-18-oic acid, b-
D-glucopyranosyl ester
Stevioside: 13-[(2-O-b-D-glucopyranosyl-b-D-glucopyranosyl)oxy]kaur-16-en-18-oic acid, b-D-
glucopyranosyl ester
Rebaudioside A: 13-[(2-O-b-D-glucopyranosyl-3-O-b-D-glucopyranosyl-b-D-glucopyranosyl)oxy]




oxy]kaur-16-en-18-oic acid, b-D-glucopyranosyl ester
Rebaudioside D: 13-[(2-O-b-D-glucopyranosyl-3-O-b-D-glucopyranosyl-b-D-glucopyranosyl)oxy]
kaur-16-en-18-oic acid, 2-O-b-D-glucopyranosyl-b-D-glucopyranosyl ester
Rebaudioside E: 13-[(2-O-b-D-glucopyranosyl-b-D-glucopyranosyl)oxy]kaur-16-en-18-oic acid,
2-O-b-D-glucopyranosyl-b-D-glucopyranosyl ester
Rebaudioside F: 13[(2-O-b-D-xylofurananosyl-3-O-b-D-glucopyranosyl-b-D-glucopyranosyl)oxy]




Where R1 and R2 can be one or more sugar moieties,
including, but not limited to glucose, rhamnose, xylose,
fructose, deoxyglucose, arabinose and galactose as
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Steviol glycosides (E 960)
Commission Regulation 231/2012
Proposed specifications for E 960 Steviol













































Assay Not less than 95% steviolbioside, rubusoside, dulcoside A, stevioside, rebaudiosides A, B, C, D,
E, F and M, on the dried basis, in any combination and ratio
Not less than 95% of total steviol glycosides on
the dried basis
Description White to light yellow powder, approximately between 200 and 350 times sweeter than sucrose
(at 5% sucrose equivalency).
White to light yellow powder, approximately between
200 and 350 times sweeter than sucrose (at 5% sucrose
equivalency)
Identification
Solubility Freely soluble to slightly soluble in water Freely soluble to slightly soluble in water
pH Between 4,5 and 7,0 (1 in 100 solution) Between 4,5 and 7,0 (1 in 100 solution)
Purity
Total ash Not more than 1% Not more than 1%
Loss on drying Not more than 6% (105 °C, 2 h) Not more than 6% (105 °C, 2 h)
Residual solvent Not more than 200 mg/kg methanol Not more than 200 mg/kg methanol
Not more than 5000 mg/kg ethanol Not more than 5,000 mg/kg ethanol
Arsenic Not more than 1 mg/kg Not more than 1 mg/kg





Not more than 1,000 CFU/g
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Steviol glycosides (E 960)
Commission Regulation 231/2012
Proposed specifications for E 960 Steviol
(Documentation provided to EFSA n. 1)
Yeast and
moulds
Not more than 200 CFU/g
E. coli Negative in 1 g
Salmonella Negative in 25 g
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6 days incubation Anaerobial
caecal
bacterial cells
HPLC Stevioside was completely
transformed into steviol within
2 days
Rebaudioside A was transformed
into steviol after 6 days
Both stevioside and
rebaudioside A can be
degraded to steviol by
microbiota in the mammalian
lower bowel with a
degradation rate ranging
between 0.4 and 0.8 mg
converted/h per g caecal
contents
In vivo Steviol-17-[14C] Oral in suspension
1 ml (1.7 uCi,







absorbed from the bowel after oral
administration. The radioactivity



































In blood: [3H] Stevioside reached
Cmax at 8 hours and then
decreased slowly with an
elimination half-life of 24 hours
In urine and faeces: Faecal
excretion was 68% and urinary
excretion was 2.3% at 120 hours,
respectively.
Tissues distribution: in the
stomach and small intestine, the
highest levels were reached at
1 hour and in the caecum, the
highest concentration was reached
at 4 hours.
Less than 1% of [3H] Stevioside
was found in other tissues after
1 hour.
Radiochromatogram of metabolites
showed that in the stomach and
faeces steviol was the main
metabolites. Other metabolites
were detected but not identified
[3H] Stevioside concentration
reached higher concentration
at 1 hour and 4 hours after
the administration in the GI
tract and in the blood,
respectively. Most of the
compound stays in the GI
tract with low distribution in
other organs. Stevioside
hydrolysed into steviol in the
intestine and mainly
excreted via faeces
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available or of HPLC
grade

















Stevioside is hydrolysed into steviol
and similarly
monoglucosylstevioside is first a-
deglucosilate and then hydrolysed
to steviol.
Rebaudioside A and a-
monoglucosylrebaudioside A are
eventually hydrolysed to steviol
mainly via stevioside.
No degradation of steviol was
found after 24 hours incubation
period and no other peaks were
found for steviol of stevia mixture
and enzymatically modified stevia
Steviol is confirmed as the
final metabolite from stevia
mixture and enzymatically



















HPLC Stevioside was completely
degraded into steviol in
approximately 10 hours.
Rebaudioside A was completely
degraded into steviol in
approximately 24 hours.
Steviol remained unchanged for




A to the common aglycon
steviol in 10 and 24 hours,















LC/MS Stevioside was detected in 7 out of
9 subjects at 1 hour after dosing
Stevioside is absorbed after
oral administration and
steviol-glucoronide was the
only metabolite found in
plasma and in urine. Steviol
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In vivo Human Stevioside (97%
purity)
Stevioside 250 mg
capsules 9 3 time
a day for 3 days
Urine IR/NMR Steviol-glucoronide was the only
metabolite detected in the urine.
No free steviol was found
As only steviol-glucoronide
was the detected in the
urine, it is suggested that
stevioside is degraded into
steviol by colon microbioma

















LC/MS/MS Steviol was detected only in one
subject whether steviol-
glucuronide was found in plasma
samples. Steviol-glucuronide
derived from rebaudioside A
showed a peak at 12 hours,
Steviol-glucuronide derived from
stevioside showed a peak at
8 hours.
Steviol-glucuronide was primary
excreted in the urine and was not
found in the faeces
Rebaudioside A and
stevioside are hydrolysed to
steviol in the GI tract. The
main circulating metabolite is
Steviol-glucuronide which is
then excreted in the urine.
Rebaudioside A has one
additional glucose moiety
that must be removed
before hydrolysation and this
can explain the lower Cmax






















Main radioactive metabolite was
steviol and in lower amount
steviol-glucoronide.
Steviol was most component in
faeces
Rebaudioside A and
stevioside are metabolised to
steviol by gut microbioma
and excreted in the faeces.
Steviol-glucoronide was
present in the urine
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0.2 or 2 mg/ml of
each rebaudioside




LC/MS In vitro metabolism of
rebaudioside A, B and D are
comparable. At 0.2 mg/ml
rebaudioside A degraded to steviol
(> 88%) within 8 h and was
completely metabolised by 24 h.
Similarly, rebaudioside D was
degraded into steviol by 8 hours
and rebaudioside B had lower level
on degradation to 83% into steviol
after 8 hours incubation.
Rebaudioside A, B and D at
2 mg/ml showed slower
metabolism to steviol compared to
0.2 mg/ml but still showing full
conversion to steviol at 24 h.
Rebaudioside M was tested at
0.2 mg/ml and showed a slower
rate of metabolism after 8 h
incubation. Rebaudioside M was
fully degraded at 16 h
Rebaudioside A, B, D and M
also defined as parent steviol
glycosides, were degraded
by gut microbioma to steviol
within 24 hours but with the
majority metabolised at
8 hours. No significant
differences have been
identified between
rebaudioside A and other
rebaudiosides except for the
slower rate of degradation of
rebaudioside D and M
compared to rebaudioside A,
which could be explained by
the additional glucose moiety










0.2 and 2 mg/mL
Human faecal
homogenate
LC/MS/MS Rebaudioside E at 0.2 mg/ml was
metabolised to steviolbioside and
steviol within 24 h incubation
period. The intermediate
metabolites steviolbioside was
found at 4 h and 8 h samples but
then was not found at 24 h.
Incubation of rebaudioside E at




were identified in the
metabolism between
rebaudioside A and E, which
are both degraded to steviol




then hydrolysed into steviol
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LC/MS At 2 mg/mL, rebaudioside A, B
and D were metabolised up to
17% at 8 h and at up to 102% of
hydrolysis at 24 h. The rats of
metabolism at 0.2 mg/mL were
quicker.
At 2 mg/mL, Rebaudioside C has
slower rate of hydrolysis compared
to Rebaudioside A.
At 2 mg/mL, Rebaudioside M
achieved complete hydrolysis at
16 h.
At 2 mg/mL, Rebaudioside E has
similar rate of hydrolysis than
rebaudioside A.
Rebaudioside F showed solubility
issue at 2 mg/mL. At 0.2 and
2 mg/mL rate of hydrolysis was
slower than rebaudioside A
At 2 mg/ml rebaudioside A,
B, C and D were completely
hydrolysed within 48 hours,
whether at lower
concentration of 0.2 mg/mL
the hydrolysis rate was more
rapid.
For rebaudioside A, B and E
at 24 h approximately
50–80% of hydrolysis takes
place, whether for
rebaudioside C and D the
level of hydrolysis ranges
from 20–46% and 60–100%,
respectively, at 24 h.
Rebaudioside F has the
lowest rate of hydrolysis with














Blood, tissues LC/MS/MS After stevioside administration at
40 mg/kg bw, steviol was
detectable from 2 h post-dose and
reached Cmax between 2 and
6 hours post-dose. Steviol was not
detectable at 36 h. At 1,000 mg/
kg bw, steviol was detected from
1 h post-dose reaching th Cmax
between 6 and 12 h post-dose.
Steviol was not detected at 72 h
post-dose
In humans, Cmax for steviol
occurred slightly later than in
rats. AUC to steviol in
humans were approximately
2.8-fold higher than in rats
Human Stevioside at
40 mg/kg bw
Blood Cmax of steviol was reached
between 19 and 20 h post-dose
after administration of 40 mg/kg
bw stevioside. Steviol was below
limit of detection at 48 h post-
dose
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